Coherus Oncology, Inc.
CHRSNasdaq
$1.40
↑ +0.7%Jul 17 close · end-of-day
Price
1Y↑ +55.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$191.0M
Enterprise Value
$23.9M
P/E
0.9
P/S
4.1
P/B
2.4
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$46.9M
Net Income (TTM)
$186.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-366.6%
Net Margin
397.3%
ROE
236.9%
ROIC
—
Debt / Equity
—
Net Cash
$167.0M
Return 1Y
+56.3%
Company profile
Coherus BioSciences, Inc. markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor. Pipeline products include biosimilars of Humira, Avastin, and Lucentis. Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China.
- CEO
- Denny M. Lanfear
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 330
- Headquarters
- California
- Website
- coherus.com
Management & directors
- Lanfear Dennis MPresident & CEO
- Mcmichael Bryan JChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
CHRS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$12.3M↑ +62.0%
Diluted EPS-$0.28↓ -42.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $475.8M | $326.6M | $211.0M | $1.2M | $26.4M | $42.2M |
| Gross profit | — | — | — | — | — | — |
| Operating income | $156.3M | -$263.9M | -$256.9M | -$215.8M | -$199.7M | -$181.1M |
| Net income | $132.2M | -$287.1M | -$291.8M | -$237.9M | $28.5M | $168.0M |
| Diluted EPS | $1.62 | -$3.81 | -$3.76 | -$2.53 | $0.25 | $1.43 |
| Operating cash flow | $154.1M | -$37.4M | -$241.1M | -$174.9M | -$20.4M | -$138.5M |
| Free cash flow | $146.9M | -$38.7M | -$243.2M | -$175.2M | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 32.9% | -80.8% | -121.7% | -17716.6% | -756.6% | -429.5% |
| Net margin | 27.8% | -87.9% | -138.2% | -19531.4% | 108.0% | 398.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.3M | $6.1M | $7.7M | $7.6M | $10.3M | $11.6M | $12.7M | $12.3M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$39.6M | -$46.9M | -$45.4M | -$45.4M | -$45.5M | -$44.3M | -$45.9M | -$36.2M |
| Net income | -$12.9M | -$10.8M | -$50.7M | -$56.6M | $297.8M | -$35.5M | -$37.6M | -$38.3M |
| Diluted EPS | -$0.11 | -$0.09 | -$0.46 | -$0.49 | $2.57 | -$0.31 | -$0.34 | -$0.28 |
| Operating cash flow | $59.7M | -$62.0M | $28.6M | -$25.8M | -$46.6M | -$46.3M | -$19.7M | -$57.9M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -384.9% | -774.2% | -586.9% | -597.9% | -443.6% | -383.1% | -359.9% | -293.7% |
| Net margin | -125.5% | -177.6% | -655.6% | -744.4% | 2903.9% | -307.1% | -295.3% | -311.3% |
Company news
May 12, 2026
May 11, 2026
- 69d agoCoherus Oncology Q1 Earnings Call Highlightsmarketbeat.com
- 69d agoCoherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimatesfinance.yahoo.com
- 70d agoCoherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Updatefinance.yahoo.com
- 70d agoHere Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More247wallst.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-05 | Satvat Ali J. | Award | 30,000 | $0.00 | $0.00 | filing |
| 2026-06-05 | Karachun Rita A | Award | 30,000 | $0.00 | $0.00 | filing |
| 2026-06-05 | Newcomer Lee Nisley | Award | 30,000 | $0.00 | $0.00 | filing |
| 2026-06-05 | Ryan Michael Lee | Award | 30,000 | $0.00 | $0.00 | filing |
| 2026-06-05 | O'Donnell-Tormey Jill | Award | 30,000 | $0.00 | $0.00 | filing |
| 2026-06-05 | Wahlstrom Mats | Award | 30,000 | $0.00 | $0.00 | filing |
| 2026-06-05 | Newton Charles W. | Award | 30,000 | $0.00 | $0.00 | filing |
| 2026-01-23 | Lanfear Dennis M· President & CEO | Award | 375,000 | $0.00 | $0.00 | filing |
| 2026-01-22 | McMichael Bryan J· Chief Financial Officer | Award | 112,500 | $0.00 | $0.00 | filing |
| 2026-01-20 | Lanfear Dennis M· President & CEO | Tax withholding | 11,839 | $1.55 | $18,350.45 | filing |
| 2026-01-20 | McMichael Bryan J· Chief Financial Officer | Tax withholding | 1,715 | $1.55 | $2,658.25 | filing |
Latest 11 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.